Saskia N de Wildt,Nobuko Taguchi,Gideon Koren
Saskia N de Wildt
Background: A 27-year-old woman with upper mediastinum stage IIA Hodgkin lymphoma was treated with six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy. Two months later she received a total of ...
Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men? [0.03%]
氟达拉滨、环磷酰胺和利妥昔单抗治疗慢性淋巴细胞白血病：还有老年人的容身之地吗？
Terry J Hamblin
Terry J Hamblin
The combination of fludarabine, cyclophosphamide and rituximab is regarded as the gold-standard treatment for chronic lymphocytic leukemia in many parts of the world, although rituximab has not yet been licensed for this use. To date, no ra...
Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer? [0.03%]
卡铂联合依托泊苷或伊立替康治疗小细胞肺癌的效果和安全性哪个性价比更高？
Alexander Schmittel,Ulrich Keilholz
Alexander Schmittel
Little progress has been made in the treatment of small cell lung cancer over the past two decades. Superiority of combined irinotecan-cisplatin over standard etoposide-cisplatin in a Japanese phase III trial was not confirmed in two subseq...
Optimal timing of surgery after preoperative chemoradiotherapy for rectal cancer [0.03%]
术前放化疗后直肠癌手术时机的研究
Lars Påhlman
Lars Påhlman
The timing of surgery in rectal cancer treatment after neoadjuvant chemoradiotherapy is debated, mainly because of downsizing and repopulation of tumor cells. The retrospective analysis of prospectively collected data from a series of patie...
Allison R Larson,Eliz Konat,Rhoda M Alani
Allison R Larson
Melanoma is the leading cause of death from skin cancer in industrialized countries. Clinical and histological variables such as primary tumor invasion, ulceration, and lymph node status might fail to identify early-stage disease that will ...
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer [0.03%]
赫捷，曲妥珠单抗作为HER2阳性早期乳腺癌的系统性治疗药物
Gabriella Mariani,Angelica Fasolo,Elena De Benedictis et al.
Gabriella Mariani et al.
Trastuzumab has an established role for the treatment of HER2-positive early-stage breast cancer because of the success of this agent in the adjuvant setting. Several key questions about the value of trastuzumab for the treatment of breast ...
Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma [0.03%]
对于肾细胞癌患者，索拉非尼在生活质量方面优于干扰素α疗法
Lisa M Pickering,Linda Pyle,James M G Larkin
Lisa M Pickering
Randomized trials have shown that both anti-vascular endothelial growth factor (VEGF) therapy and inhibition of the mammalian target of rapamycin have superior clinical efficacy when compared with interferon alpha in the first-line treatmen...
Edward S Kim
Edward S Kim
Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma [0.03%]
适合于皮肤黑色素瘤的诊断和治疗的哨点淋巴结活检需求分析
Ettore Minutilli,Uwe Trefzer,Eggert Stockfleth et al.
Ettore Minutilli et al.
Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy [0.03%]
间歇用靶向药物作为减少酪氨酸激酶抑制剂治疗毒性的工具
Giovanni Martinelli,Simona Soverini,Ilaria Iacobucci et al.
Giovanni Martinelli et al.
Tyrosine kinase inhibitor therapy has revolutionized the outcome of chronic myeloid leukemia (CML), and has transformed a fatal disease into a chronic condition for most patients. At present, the therapeutic armamentarium against CML includ...